Day: June 27, 2024

Posted on

Fortrea Launches AI Innovation Studio to Galvanize Technology and Human Solutions to Improve Clinical Trial Delivery

DURHAM, N.C., June 27, 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced the launch of its artificial intelligence (AI) Innovation Studio, signaling a strategic investment in reshaping the execution of clinical trials today and into the future.

The studio will develop and deploy AI and machine learning (ML) technologies to drive speed, agility, quality and enhanced patient safety in the clinical research process by equipping and empowering people to focus on the critical human element of clinical trials.

“Patients around the world are waiting for novel, life-changing treatments. With AI, we now have the power—and the obligation—to help deliver solutions to them faster,” said Fortrea’s Chief Information Officer Alejandro Martinez Galindo.

“Fortrea’s AI Innovation Studio will enable enhanced technological capabilities that will allow AI-enabled systems to perform cutting-edge processes—such as trial simulations, predictive analytics and pattern recognition—as well as repetitive, administrative, ‘machine-friendly tasks’. This frees up people to contribute human creativity and connection to the clinical trial of tomorrow and focus on what counts: the patient.”

Fortrea’s AI Innovation Studio aims to:

  • Partner across Fortrea and with our customers to provide technology solutions for bespoke site and sponsor innovation strategies;
  • Develop net new, greenfield technology innovations that holistically improve the delivery of clinical trials for sponsors, sites, patients and our teams; and
  • Support existing infrastructure and operations with enhanced technology to enable new, improved ways of working and create best-in-class user experiences.

Technologies under development in the studio include smartphone-enabled data collection; specialized large language models for text comprehension and generation; symbolic AI with real-valued logic (i.e., building decision logic using real-world scenarios and data); mixed reality and augmented intelligence; advanced data mining and predictive analytics; and digital twinning.

Strategic application of these technologies is expected to result in meaningful advancements in patient recruitment and retention, protocol creation/optimization, risk-based quality monitoring and overall delivery speed and quality. These technologies can also deliver an improved patient experience and greater productivity for Fortrea customers, sites and employees.

Developments from the AI Innovation Studio will be critical to Fortrea’s clinical technology platform, which is being designed to integrate clinical trial technology into a consumer-grade, location-agnostic, omni-channel, persona-based experience accessible thorough a single screen.

“Fortrea is focused on a future vision of the CRO industry, allowing us to build TO the future rather than FROM the past,” said Brian Dolan, Vice President of Artificial Intelligence & Machine Learning. “We are exercising great care and consideration to the responsible and ethical development and deployment of AI, prioritizing doing the right thing for the right reasons and protecting patient safety and privacy, and the intellectual property of our customers.”

About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life-changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter).

Fortrea Contacts:
Hima Inguva (Investors) – 877-495-0816, hima.inguva@fortrea.com
Jennifer Minx (Media) – 919-410-4195, media@fortrea.com
Kate Dillon (Media) – 646-818-9115, kdillon@prosek.com

GlobeNewswire Distribution ID 9170022

Posted on

Fortrea Launches AI Innovation Studio to Galvanize Technology and Human Solutions to Improve Clinical Trial Delivery

DURHAM, N.C., June 27, 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced the launch of its artificial intelligence (AI) Innovation Studio, signaling a strategic investment in reshaping the execution of clinical trials today and into the future.

The studio will develop and deploy AI and machine learning (ML) technologies to drive speed, agility, quality and enhanced patient safety in the clinical research process by equipping and empowering people to focus on the critical human element of clinical trials.

“Patients around the world are waiting for novel, life-changing treatments. With AI, we now have the power—and the obligation—to help deliver solutions to them faster,” said Fortrea’s Chief Information Officer Alejandro Martinez Galindo.

“Fortrea’s AI Innovation Studio will enable enhanced technological capabilities that will allow AI-enabled systems to perform cutting-edge processes—such as trial simulations, predictive analytics and pattern recognition—as well as repetitive, administrative, ‘machine-friendly tasks’. This frees up people to contribute human creativity and connection to the clinical trial of tomorrow and focus on what counts: the patient.”

Fortrea’s AI Innovation Studio aims to:

  • Partner across Fortrea and with our customers to provide technology solutions for bespoke site and sponsor innovation strategies;
  • Develop net new, greenfield technology innovations that holistically improve the delivery of clinical trials for sponsors, sites, patients and our teams; and
  • Support existing infrastructure and operations with enhanced technology to enable new, improved ways of working and create best-in-class user experiences.

Technologies under development in the studio include smartphone-enabled data collection; specialized large language models for text comprehension and generation; symbolic AI with real-valued logic (i.e., building decision logic using real-world scenarios and data); mixed reality and augmented intelligence; advanced data mining and predictive analytics; and digital twinning.

Strategic application of these technologies is expected to result in meaningful advancements in patient recruitment and retention, protocol creation/optimization, risk-based quality monitoring and overall delivery speed and quality. These technologies can also deliver an improved patient experience and greater productivity for Fortrea customers, sites and employees.

Developments from the AI Innovation Studio will be critical to Fortrea’s clinical technology platform, which is being designed to integrate clinical trial technology into a consumer-grade, location-agnostic, omni-channel, persona-based experience accessible thorough a single screen.

“Fortrea is focused on a future vision of the CRO industry, allowing us to build TO the future rather than FROM the past,” said Brian Dolan, Vice President of Artificial Intelligence & Machine Learning. “We are exercising great care and consideration to the responsible and ethical development and deployment of AI, prioritizing doing the right thing for the right reasons and protecting patient safety and privacy, and the intellectual property of our customers.”

About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life-changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter).

Fortrea Contacts:
Hima Inguva (Investors) – 877-495-0816, hima.inguva@fortrea.com
Jennifer Minx (Media) – 919-410-4195, media@fortrea.com
Kate Dillon (Media) – 646-818-9115, kdillon@prosek.com

GlobeNewswire Distribution ID 9170022

Posted on

Fortrea Launches AI Innovation Studio to Galvanize Technology and Human Solutions to Improve Clinical Trial Delivery

DURHAM, N.C., June 27, 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced the launch of its artificial intelligence (AI) Innovation Studio, signaling a strategic investment in reshaping the execution of clinical trials today and into the future.

The studio will develop and deploy AI and machine learning (ML) technologies to drive speed, agility, quality and enhanced patient safety in the clinical research process by equipping and empowering people to focus on the critical human element of clinical trials.

“Patients around the world are waiting for novel, life-changing treatments. With AI, we now have the power—and the obligation—to help deliver solutions to them faster,” said Fortrea’s Chief Information Officer Alejandro Martinez Galindo.

“Fortrea’s AI Innovation Studio will enable enhanced technological capabilities that will allow AI-enabled systems to perform cutting-edge processes—such as trial simulations, predictive analytics and pattern recognition—as well as repetitive, administrative, ‘machine-friendly tasks’. This frees up people to contribute human creativity and connection to the clinical trial of tomorrow and focus on what counts: the patient.”

Fortrea’s AI Innovation Studio aims to:

  • Partner across Fortrea and with our customers to provide technology solutions for bespoke site and sponsor innovation strategies;
  • Develop net new, greenfield technology innovations that holistically improve the delivery of clinical trials for sponsors, sites, patients and our teams; and
  • Support existing infrastructure and operations with enhanced technology to enable new, improved ways of working and create best-in-class user experiences.

Technologies under development in the studio include smartphone-enabled data collection; specialized large language models for text comprehension and generation; symbolic AI with real-valued logic (i.e., building decision logic using real-world scenarios and data); mixed reality and augmented intelligence; advanced data mining and predictive analytics; and digital twinning.

Strategic application of these technologies is expected to result in meaningful advancements in patient recruitment and retention, protocol creation/optimization, risk-based quality monitoring and overall delivery speed and quality. These technologies can also deliver an improved patient experience and greater productivity for Fortrea customers, sites and employees.

Developments from the AI Innovation Studio will be critical to Fortrea’s clinical technology platform, which is being designed to integrate clinical trial technology into a consumer-grade, location-agnostic, omni-channel, persona-based experience accessible thorough a single screen.

“Fortrea is focused on a future vision of the CRO industry, allowing us to build TO the future rather than FROM the past,” said Brian Dolan, Vice President of Artificial Intelligence & Machine Learning. “We are exercising great care and consideration to the responsible and ethical development and deployment of AI, prioritizing doing the right thing for the right reasons and protecting patient safety and privacy, and the intellectual property of our customers.”

About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life-changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter).

Fortrea Contacts:
Hima Inguva (Investors) – 877-495-0816, hima.inguva@fortrea.com
Jennifer Minx (Media) – 919-410-4195, media@fortrea.com
Kate Dillon (Media) – 646-818-9115, kdillon@prosek.com

GlobeNewswire Distribution ID 9170022

Posted on

Fortrea Launches AI Innovation Studio to Galvanize Technology and Human Solutions to Improve Clinical Trial Delivery

DURHAM, N.C., June 27, 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced the launch of its artificial intelligence (AI) Innovation Studio, signaling a strategic investment in reshaping the execution of clinical trials today and into the future.

The studio will develop and deploy AI and machine learning (ML) technologies to drive speed, agility, quality and enhanced patient safety in the clinical research process by equipping and empowering people to focus on the critical human element of clinical trials.

“Patients around the world are waiting for novel, life-changing treatments. With AI, we now have the power—and the obligation—to help deliver solutions to them faster,” said Fortrea’s Chief Information Officer Alejandro Martinez Galindo.

“Fortrea’s AI Innovation Studio will enable enhanced technological capabilities that will allow AI-enabled systems to perform cutting-edge processes—such as trial simulations, predictive analytics and pattern recognition—as well as repetitive, administrative, ‘machine-friendly tasks’. This frees up people to contribute human creativity and connection to the clinical trial of tomorrow and focus on what counts: the patient.”

Fortrea’s AI Innovation Studio aims to:

  • Partner across Fortrea and with our customers to provide technology solutions for bespoke site and sponsor innovation strategies;
  • Develop net new, greenfield technology innovations that holistically improve the delivery of clinical trials for sponsors, sites, patients and our teams; and
  • Support existing infrastructure and operations with enhanced technology to enable new, improved ways of working and create best-in-class user experiences.

Technologies under development in the studio include smartphone-enabled data collection; specialized large language models for text comprehension and generation; symbolic AI with real-valued logic (i.e., building decision logic using real-world scenarios and data); mixed reality and augmented intelligence; advanced data mining and predictive analytics; and digital twinning.

Strategic application of these technologies is expected to result in meaningful advancements in patient recruitment and retention, protocol creation/optimization, risk-based quality monitoring and overall delivery speed and quality. These technologies can also deliver an improved patient experience and greater productivity for Fortrea customers, sites and employees.

Developments from the AI Innovation Studio will be critical to Fortrea’s clinical technology platform, which is being designed to integrate clinical trial technology into a consumer-grade, location-agnostic, omni-channel, persona-based experience accessible thorough a single screen.

“Fortrea is focused on a future vision of the CRO industry, allowing us to build TO the future rather than FROM the past,” said Brian Dolan, Vice President of Artificial Intelligence & Machine Learning. “We are exercising great care and consideration to the responsible and ethical development and deployment of AI, prioritizing doing the right thing for the right reasons and protecting patient safety and privacy, and the intellectual property of our customers.”

About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life-changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter).

Fortrea Contacts:
Hima Inguva (Investors) – 877-495-0816, hima.inguva@fortrea.com
Jennifer Minx (Media) – 919-410-4195, media@fortrea.com
Kate Dillon (Media) – 646-818-9115, kdillon@prosek.com

GlobeNewswire Distribution ID 9170022

Posted on

STMA holds ninth assembly meeting


Mr Abdul Mumin-Issah, the Metropolitan Chief Executive of the Sekondi-Takoradi Metropolitan Assembly (STMA), says the Assembly internally generated an amount of more than GHS13.3 million as of December 2023.

This is compared to a budgeted revenue of more than GHS17.5 million for the period under review.

Also, Government grants comprising DACF, MPs and PWD amounted to over GHS3.2 million, representing 44.57% of GHS7.3 million estimated for the period.

The Assembly received funds from donor partners amounting to GHS13.1 million, which represented 102.55 per cent of the budgeted GHS12.8 million.

The Metropolitan Chief Executive, who announced this at the 19th assembly meeting in Sekondi, said management would continue to intensify efforts at enhancing revenue generation for the Assembly to enable it to meet the developmental needs of the people.

Meanwhile, the Assembly would remain committed to making available the necessary logistical support to the security agencies to enable them to discharge their dutie
s in a professional manner.

‘The Assembly will continue to work hard to ensure that individuals and businesses go about their daily activities in a safe and secure environment.’

Mr Mumin-Issah said STMA, through the Metro Agriculture Director was sensitizing stakeholders on registration processes for the second phase of the Planting for Food and Jobs and urged them to extend the information to farmers in their respective communities.

He said, so far, 100 farmers had been registered.

The MCE said desilting drains which had been allocated to various contractors was ongoing in the various communities marked as high-risk flood-prone areas to ensure a cleaner, safer and more resilient environment for the residents.

The MCE said the second phase of the E-Tankas initiative would focus on community watch, where community members could download the application to lodge complaints.

The Assembly has so far realized GH?25,000.00 from the E-Tankas initiative.

He announced the progress of Work on Axim Road, Shippers
Council Road, De-graft Johnson Road, Harbour Road, Sekondi Road and Adiembra Road, ‘ work on these roads has been ongoing since August 15, 2022. As of the end of February 2024, contractors had been on site for 18 months representing 75 per cent of time spent on site.’

He said the PTC Interchange project had remained suspended for some time now with Sino-hydro, the main contractor for the project vacating the project site since January 2023.

The Sekondi-Takoradi Market and Transport Infrastructure Project, which involved the Redevelopment of the Sekondi market into an ultramodern market, Construction of an automated multi-storey car park in Takoradi (Beach Road taxi station),

Redevelopment of the Eburufom Market and Main Spain (Amanful Electoral Area), Construction of a Haulage Terminal at Sofokrom and Bus Terminal at Nkroful junction had secured a Transactional Advisor to conduct a full feasibility and selection of a suitable private investor to develop the project.

In recognition of the untapped potentia
l of recycling non-biodegradable materials like plastic, as a sustainable livelihood option for the teeming unemployed youth in the Metropolis, the Twins- Cities in Sustainable Partnership Project established and equipped a plastic recycling workshop at the TCSPP Skills and Entrepreneurship Training Centre at STMA Depot, in Sekondi, MCE added.

Source: Ghana News Agency

Posted on

STMA holds ninth assembly meeting


Mr Abdul Mumin-Issah, the Metropolitan Chief Executive of the Sekondi-Takoradi Metropolitan Assembly (STMA), says the Assembly internally generated an amount of more than GHS13.3 million as of December 2023.

This is compared to a budgeted revenue of more than GHS17.5 million for the period under review.

Also, Government grants comprising DACF, MPs and PWD amounted to over GHS3.2 million, representing 44.57% of GHS7.3 million estimated for the period.

The Assembly received funds from donor partners amounting to GHS13.1 million, which represented 102.55 per cent of the budgeted GHS12.8 million.

The Metropolitan Chief Executive, who announced this at the 19th assembly meeting in Sekondi, said management would continue to intensify efforts at enhancing revenue generation for the Assembly to enable it to meet the developmental needs of the people.

Meanwhile, the Assembly would remain committed to making available the necessary logistical support to the security agencies to enable them to discharge their dutie
s in a professional manner.

‘The Assembly will continue to work hard to ensure that individuals and businesses go about their daily activities in a safe and secure environment.’

Mr Mumin-Issah said STMA, through the Metro Agriculture Director was sensitizing stakeholders on registration processes for the second phase of the Planting for Food and Jobs and urged them to extend the information to farmers in their respective communities.

He said, so far, 100 farmers had been registered.

The MCE said desilting drains which had been allocated to various contractors was ongoing in the various communities marked as high-risk flood-prone areas to ensure a cleaner, safer and more resilient environment for the residents.

The MCE said the second phase of the E-Tankas initiative would focus on community watch, where community members could download the application to lodge complaints.

The Assembly has so far realized GH?25,000.00 from the E-Tankas initiative.

He announced the progress of Work on Axim Road, Shippers
Council Road, De-graft Johnson Road, Harbour Road, Sekondi Road and Adiembra Road, ‘ work on these roads has been ongoing since August 15, 2022. As of the end of February 2024, contractors had been on site for 18 months representing 75 per cent of time spent on site.’

He said the PTC Interchange project had remained suspended for some time now with Sino-hydro, the main contractor for the project vacating the project site since January 2023.

The Sekondi-Takoradi Market and Transport Infrastructure Project, which involved the Redevelopment of the Sekondi market into an ultramodern market, Construction of an automated multi-storey car park in Takoradi (Beach Road taxi station),

Redevelopment of the Eburufom Market and Main Spain (Amanful Electoral Area), Construction of a Haulage Terminal at Sofokrom and Bus Terminal at Nkroful junction had secured a Transactional Advisor to conduct a full feasibility and selection of a suitable private investor to develop the project.

In recognition of the untapped potentia
l of recycling non-biodegradable materials like plastic, as a sustainable livelihood option for the teeming unemployed youth in the Metropolis, the Twins- Cities in Sustainable Partnership Project established and equipped a plastic recycling workshop at the TCSPP Skills and Entrepreneurship Training Centre at STMA Depot, in Sekondi, MCE added.

Source: Ghana News Agency

Posted on

STMA holds ninth assembly meeting


Mr Abdul Mumin-Issah, the Metropolitan Chief Executive of the Sekondi-Takoradi Metropolitan Assembly (STMA), says the Assembly internally generated an amount of more than GHS13.3 million as of December 2023.

This is compared to a budgeted revenue of more than GHS17.5 million for the period under review.

Also, Government grants comprising DACF, MPs and PWD amounted to over GHS3.2 million, representing 44.57% of GHS7.3 million estimated for the period.

The Assembly received funds from donor partners amounting to GHS13.1 million, which represented 102.55 per cent of the budgeted GHS12.8 million.

The Metropolitan Chief Executive, who announced this at the 19th assembly meeting in Sekondi, said management would continue to intensify efforts at enhancing revenue generation for the Assembly to enable it to meet the developmental needs of the people.

Meanwhile, the Assembly would remain committed to making available the necessary logistical support to the security agencies to enable them to discharge their dutie
s in a professional manner.

‘The Assembly will continue to work hard to ensure that individuals and businesses go about their daily activities in a safe and secure environment.’

Mr Mumin-Issah said STMA, through the Metro Agriculture Director was sensitizing stakeholders on registration processes for the second phase of the Planting for Food and Jobs and urged them to extend the information to farmers in their respective communities.

He said, so far, 100 farmers had been registered.

The MCE said desilting drains which had been allocated to various contractors was ongoing in the various communities marked as high-risk flood-prone areas to ensure a cleaner, safer and more resilient environment for the residents.

The MCE said the second phase of the E-Tankas initiative would focus on community watch, where community members could download the application to lodge complaints.

The Assembly has so far realized GH?25,000.00 from the E-Tankas initiative.

He announced the progress of Work on Axim Road, Shippers
Council Road, De-graft Johnson Road, Harbour Road, Sekondi Road and Adiembra Road, ‘ work on these roads has been ongoing since August 15, 2022. As of the end of February 2024, contractors had been on site for 18 months representing 75 per cent of time spent on site.’

He said the PTC Interchange project had remained suspended for some time now with Sino-hydro, the main contractor for the project vacating the project site since January 2023.

The Sekondi-Takoradi Market and Transport Infrastructure Project, which involved the Redevelopment of the Sekondi market into an ultramodern market, Construction of an automated multi-storey car park in Takoradi (Beach Road taxi station),

Redevelopment of the Eburufom Market and Main Spain (Amanful Electoral Area), Construction of a Haulage Terminal at Sofokrom and Bus Terminal at Nkroful junction had secured a Transactional Advisor to conduct a full feasibility and selection of a suitable private investor to develop the project.

In recognition of the untapped potentia
l of recycling non-biodegradable materials like plastic, as a sustainable livelihood option for the teeming unemployed youth in the Metropolis, the Twins- Cities in Sustainable Partnership Project established and equipped a plastic recycling workshop at the TCSPP Skills and Entrepreneurship Training Centre at STMA Depot, in Sekondi, MCE added.

Source: Ghana News Agency

Posted on

Five Ghanaian MPs on official visit to Kenya are safe – Parliamentary Service


Five Ghanaian Legislatures and an Officer, who were on an official visit to the Parliament of Kenya, who were caught up during the Kenyan violent protest are safe and secured.

A statement issued by the Parliamentary Service of Ghana, copied to the Ghana News Agency said the High Commission of Ghana in Kenya had confirmed that the five Members of Parliament (MPs) and the Officer accompanying the delegation are safe and secure.

It said the delegation, which was made up of some members of the Local Government Committee of Parliament, including Mr Emmanuel Akwasi Gyamfi, the Chairman of the Committee; Mr Edwin Nii Lante Vanderpuye, the Ranking Member of the Committee,

The rest are Mr Sylvester Tetteh, Mr Thomas Ampem Nyarko, Mr Mohammed Taferu and Madam Anita Quartey Papafio, a Senior Principal Assistant Clerk.

The statement said the delegation was in the Kenyan Parliament on a bench-marking visit when the unfortunate incident occurred.

It noted that they were immediately escorted and secured in the Senate b
uilding and finally evacuated to their hotel by Officials of the Kenyan Parliament.

‘We appreciate the concern from the general public and wish to indicate that efforts are underway to ensure their safe return to Ghana,’ the statement said.

Source: Ghana News Agency